Silence Therapeutics (SLN) Equity Average (2023 - 2026)

Silence Therapeutics' Equity Average history runs 4 years deep, the most recent figure standing at $55.9 million for Q1 2026.

• In Q1 2026, Equity Average fell 54.73% year-over-year to $55.9 million; the TTM figure through Mar 2026 stood at $55.9 million (down 54.73% YoY), while the FY2025 annual figure was $98.2 million, up 25.84% from the prior year.
• Equity Average came in at $55.9 million for Q1 2026 at Silence Therapeutics, down from $68.2 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $149.6 million in Q2 2024 to a low of $20.3 million in Q3 2023.
• A 4-year average of $89.3 million and a median of $89.0 million in 2024 frame the typical range for Equity Average.
• Across the five-year window, Equity Average surged 562.0% in 2024 and sank 54.73% in 2026, its largest moves.
• Silence Therapeutics' Equity Average stood at $23.2 million in 2023, then surged by 460.77% to $130.4 million in 2024, then plunged by 47.7% to $68.2 million in 2025, then decreased by 18.08% to $55.9 million in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $55.9 million, $68.2 million, and $84.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison